Chenxi Yin,Chang Jiang,Fangxin Liao,Yuming Rong,Wenzhuo He,Xiuyu Cai,Guifang Guo,Huijuan Qiu,Xuxian Chen,Bei Zhang,Liangping Xia. The efficacy of bevacizumab in Chinese patientswith metastatic colorectal cancer and its effect indifferent line setting. Oncol Transl Med, 2014, 13: 169-173.
The efficacy of bevacizumab in Chinese patientswith metastatic colorectal cancer and its effect indifferent line setting
  
View Full Text  View/Add Comment  Download reader
KeyWord:bevacizumab; chemotherapy; metastatic colorectal cancer; efficacy
Author NameAffiliation
Chenxi Yin State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China 
Chang Jiang State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510061, China 
Fangxin Liao State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510062, China 
Yuming Rong State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510063, China 
Wenzhuo He State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510064, China 
Xiuyu Cai State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510065, China 
Guifang Guo State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510066, China 
Huijuan Qiu State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510067, China 
Xuxian Chen State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510068, China 
Bei Zhang State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510069, China 
Liangping Xia State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
VIP Region, Sun Yat-sen University Cancer Center
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510070, China 
Hits: 4909
Download times: 5460
Abstract:
      Objective: We aimed to evaluate the effect of bevacizumab in the palliative treatment of Chinese metastatic colorectal cancer (mCRC) and its efficacy in different lines. Methods: Patients of mCRC treated with bevacizumab or not at Sun Yat-sen University Cancer Center from 2005 to 2013 were recruited as the study group and control group. The endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS) and progression free survival (PFS). The OS and PFS of first-, second- and third-line treatment groups were compared between study group and control group. Results: The median PFS of the study and the control group were 8.2 months (7.0–9.4 months), 5.7 months (4.7–6.6 months), P = 0.001; OS were 26 months (5.4–130.5 months), 18 months (16.6–19.4 months), P < 0.001, respectively. The ORR and DCR of first-, second- and third-line were 30.3% (20/66), 20% (6/30), 17.6% (3/17) and 97% (64/66), 86.7% (26/30), 100% (17/17). In the first-line chemotherapy group, the OS of the study group and the control group were 22.9 (5.4–96.7) months and 18 (16.6–19.4) months (P < 0.001); PFS were 9.4 (8.4–10.4) months and 5.7 (4.7–6.6) months (P < 0.001), respectively. While in the second- and third-line setting, only OS were statistically different, PFS had no significant difference. Conclusion: The combination of bevacizumab and chemotherapy had a promising short-term and long-term efficacy in Chinese mCRC patients than those without bevacizumab regimens, and the effect could be better reflected in the first-line treatment.
Close